



Integrated U.S. Small-Mid Cap Core Equity Fund - I Class (TQSIX)

As of June 30, 2024

General Information

| | |
|-----------------------------------------------------------------------|----------------------------|
| CUSIP | 779917707 |
| Inception Date | February 26, 2016 |
| Benchmark | Russell 2500 Index |
| Expense Information (as of the most recent Prospectus) ⁽¹⁾ | 0.74%(Gross) 0.69%(Net) |

⁽¹⁾The I-Class operates under a contractual operating expense limitation that expires on April 30, 2026.

Key Facts

| | |
|--------------------------------------------|-----------------|
| Total Assets | USD 570,901,286 |
| Portfolio Holdings Turnover ⁽²⁾ | 57.1% |
| % of Portfolio in Cash | 0.6% |
| Alpha | 3.02% |
| Standard Deviation | 20.68% |

⁽²⁾Portfolio Turnover represents 1 year period ending 12/31/23.

Past performance is not a reliable indicator of future performance.

Morningstar™

| | |
|-----------------------------|---------------|
| Overall Morningstar Rating™ | ★★★★ |
| Morningstar Category™ | Mid-Cap Blend |

Rated against 397 Mid-Cap Blend funds, as of 6/30/2024, based on risk-adjusted total return. Ratings are determined monthly and subject to change. The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its 3-, 5- and 10-year (if applicable) Morningstar Rating metrics. **Past performance is no guarantee of future results.**

Investment Objective & Strategy

The fund seeks long-term growth of capital.


The fund normally invests in small- and mid-cap U.S. companies. The fund expects to invest predominantly in common stocks, but may occasionally purchase other types of equity securities or equity-related instruments.

Our integrated approach to investing combines fundamental analysis and quantitative models to help shape our process for security selection, portfolio construction, and risk management in a systematic manner.

The portfolio is generally constructed by buying higher ranked stocks and selecting stocks to sell from those that have a lower rank, subject to overall risk controls and desired portfolio characteristics.

Calendar Year Returns (%) (NAV, total return)

■ Integrated U.S. Small-Mid Cap Core Equity Fund - I Class (TQSIX)
■ Russell 2500 Index (RUS25)



Performance (%) (NAV, total return Performance > 1yr is Annualized)

| | 3m | YTD | 1yr | 3yrs | 5yrs | Since Inception |
|-------|-------|------|-------|-------|-------|-----------------|
| TQSIX | -2.99 | 8.22 | 19.10 | 7.34 | 11.13 | 12.45 |
| RUS25 | -4.27 | 2.35 | 10.47 | -0.29 | 8.31 | 10.86 |

Performance data quoted represents past performance and is not a reliable indicator of future performance. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. To obtain the most recent month-end performance, visit troweprice.com

The average annual total return figures reflect the reinvestment of dividends and capital gains, if any.

Prior to 5 April 2023, the name of the Integrated U.S. Small-Mid Cap Core Equity Fund was the QM U.S. Small & Mid-Cap Core Equity Fund.

The fund(s) may have other share classes available that offer different investment minimums and fees. See the prospectus for details.

Risks: Small- and mid-cap stocks: Investments in securities issued by small and mid-cap companies are likely to be more volatile than investments in securities issued by larger companies. **Quantitative models:** The fund's reliance on quantitative models and the analysis of specific metrics to construct the fund's portfolio could cause the adviser to be unsuccessful in selecting companies for investment or determining the weighting of particular stocks in the portfolio. See the prospectus for more detail on the fund's principal risks.

| Top 10 Issuers (%) | Fund | RUS25 |
|-------------------------|------|-------|
| Tenet Healthcare | 0.9 | 0.2 |
| Textron | 0.9 | 0.3 |
| RPM | 0.8 | 0.2 |
| NiSource | 0.8 | 0.2 |
| Select Medical Holdings | 0.8 | 0.1 |
| Webster Financial | 0.8 | 0.1 |
| Western Union | 0.8 | 0.1 |
| Lamar Advertising | 0.8 | 0.2 |
| Hologic | 0.8 | 0.0 |
| MKS Instruments | 0.8 | 0.1 |

| Sector Diversification (%) | Fund | RUS25 |
|----------------------------|------|-------|
| Indust & Bus Svcs | 19.9 | 20.3 |
| Financials | 17.7 | 16.2 |
| Info Tech | 15.8 | 13.5 |
| Health Care | 15.8 | 11.5 |
| Cons Disc | 10.4 | 12.8 |
| Energy | 5.2 | 5.3 |
| Real Estate | 4.5 | 6.5 |
| Materials | 4.3 | 5.4 |
| Utilities | 2.3 | 2.9 |
| Comm Svcs | 2.2 | 2.4 |
| Cons Stpls | 1.4 | 3.3 |

| Portfolio Management | Managed Since | Joined Firm |
|----------------------|---------------|-------------|
| Prashant Jeyaganesh | 2017 | 2006 |
| David Corris | 2021 | 2021 |

Additional Disclosures & Definitions

Consider the investment objectives, risks, and charges and expenses carefully before investing. For a prospectus or, if available, a summary prospectus containing this and other information, call 1-855-405-6488 or visit [troweprice.com](https://www.troweprice.com). Read it carefully.

Visit <https://www.troweprice.com/en/us/glossary> for a glossary of financial terminology. FTSE/Russell, GICS and Morningstar do not accept any liability for any errors or omissions in the indexes or data, and hereby expressly disclaim all warranties of originality, accuracy, completeness, timeliness, merchantability, and fitness for a particular purpose. No party may rely on any indexes or data contained in this communication. Visit <https://www.troweprice.com/en/us/market-data-disclosures> for additional legal notices & disclaimers.

Morningstar rated the fund 4 and 4 stars among 397 and 364 Mid-Cap Blend funds for the 3- and 5-year periods (as applicable) ending 6/30/2024, respectively. The Morningstar Rating™ for funds, or "star rating", is calculated for funds with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star.

Unless otherwise noted, index returns are shown with gross dividends reinvested. Fund Assets, holdings-based analytics (excluding portfolio turnover), and portfolio attribution are calculated using T. Rowe Price's internal Investment Book of Records (IBOR). Due to timing and accounting methodology differences, IBOR data may differ from the Accounting Book of Records (ABOR) data provided by the Fund's accountant. Diversification exhibits may not add to 100% due to exclusion or inclusion of cash. Certain numbers in this report may not equal stated totals due to rounding. Unless otherwise stated, data is as of the report date.

T. Rowe Price uses the current MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting.

Unless indicated otherwise the source of all data is T. Rowe Price.

© 2024 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.

T. Rowe Price Investment Services, Inc., Distributor.

202405-3609423